

1 **Molecular diagnosis of causality in T cell mediated severe cutaneous adverse**
2 **drug reactions**

3 Ying X Teo^{1,2}, Wei Y Haw¹, Andres F Vallejo¹, Carolann McGuire¹, Jeongmin

4 Woo¹, Peter S Friedmann¹, *Marta E Polak¹, *Michael R Ardern-Jones^{1,2}

5 *joint senior authors

6 **Corresponding author(s):** 1. Michael Roger Ardern-Jones, Mailpoint 825, Clinical
7 Experimental Sciences, Faculty of Medicine, University of Southampton,
8 Southampton SO16 6YD, United Kingdom. Telephone: +44(0)23 81 205727. Email:
9 m.aj@soton.ac.uk

10 2. Marta Ewa Polak, Mailpoint 813, Clinical Experimental Sciences, Faculty of
11 Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom.
12 Telephone: +44(0)23 81 205727. Email: m.e.polak@soton.ac.uk

13 **Conflict of interest:** The authors have declared that no conflict of interest exists

14 **Keywords:**

15 Drug reaction with eosinophilia and systemic symptoms (DRESS); Drug allergy;
16 Immunology; Biomarker; Diagnostics

¹ Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton SO16 6YD, United Kingdom

² Department of Dermatology, Southampton General Hospital, University Hospitals Southampton NHS Foundation Trust
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 **Abstract**

18 **Background:**

19 One of the most severe forms of T cell mediated cutaneous adverse drug reactions is
20 'drug reaction with eosinophilia and systemic symptoms' (DRESS), hence subsequent
21 avoidance of the causal drug is imperative. However, attribution of drug culpability in
22 DRESS is challenging and standard skin allergy tests are not recommended due to
23 for patient safety reasons. We sought to identify potential biomarkers for development
24 of a diagnostic test.

25 **Methods:**

26 Peripheral blood mononuclear cells (PBMCs) from a 'discovery' cohort (n=5)
27 challenged to drug or control were analysed for transcriptomic profile. A signature
28 panel of genes was then tested in a validation cohort (n=6), and compared to tolerant
29 controls and other inflammatory conditions which can clinically mimic DRESS. A
30 scoring system to identify presence of drug hypersensitivity was developed based on
31 gene expression alterations of this panel.

32 **Results:**

33 Whole transcriptome analysis identified 4 major gene clusters including those
34 regulating T cell activation via NFAT and cytokine receptor activity. 22 differentially
35 expressed gene transcripts were identified as a DRESS signature including Type 1
36 interferon pathways and Th2 activation. The DRESS transcriptomic panel identified
37 antibiotic-DRESS cases in a validation cohort but was not altered in other inflammatory
38 conditions. Machine learning or differential expression selection of a biomarker panel
39 showed high sensitivity and specificity (100% and 85.7-100% respectively) for
40 identification of the culprit drug in DRESS.

41 Conclusion:

42 Transcriptomic analysis of DRESS revealed important insights into the key activated
43 pathways and identified a transcriptional signature which shows potential as a test with
44 high sensitivity for drug culpability attribution.

45 **Introduction**

46 Drug allergies (drug hypersensitivity) caused by T cell mediated reactions are clinically
47 distinct in their presentation from IgE-mediated drug allergy reactions and present as
48 a range of different clinical phenotypes (1), including Drug Reaction with Eosinophilia
49 and Systemic Symptoms (DRESS). DRESS typically presents with a florid skin
50 eruption combined with hallmark systemic features of fever, lymphadenopathy, blood
51 dyscrasias such as eosinophilia, and internal organ involvement (1-3). The liver is the
52 most commonly involved among the organs, found in 51–94.2% of patients; followed
53 by renal involvement, lung, cardiac and central nervous system (4-7). Future lifelong
54 avoidance of the culprit drug is crucial as DRESS can be life-threatening, reported
55 mortality being 2-6% (2, 4, 8). Confirmation of causality can be difficult if the culprit
56 drug is not clinically obvious.

57 Skin tests and oral challenge cannot be performed acutely and are generally not
58 recommended because of the risk of re-inducing DRESS. Clinical algorithms to assess
59 causality are of value, especially for post-marketing surveillance systems, but their
60 lack of confirmatory testing limits their utility to inform treatment decisions for an
61 individual patient (9). We and others have demonstrated the diagnostic use of
62 classical immunology tests to measure drug specific T cell activation (10, 11).
63 However, such *in vitro* assays are not widely available due to being labour intensive,
64 complex, and involving radioisotopes. Therefore, there is an unmet need to develop
65 a simple, quick and robust *in vitro* assay that can be undertaken widely in routine
66 diagnostic laboratories.

67 We set out to develop an *in vitro* gene transcription signature to identify drug-induced
68 T cell activation because reverse transcriptase polymerase chain reaction (RT-PCR)

69 based assays are already widely employed in clinical laboratories and therefore this
70 approach would be scalable to routine laboratories. To determine the optimal
71 biomarkers for drug T cell activation, we undertook ribonucleic acid-sequencing (RNA-
72 seq) of drug-exposed peripheral blood mononuclear cells (PBMCs) from antibiotic-
73 induced DRESS cases. Differential expression from control samples identified
74 candidate genes as markers of drug hypersensitivity, which were further validated
75 against a second cohort, against tolerant controls and in other inflammatory
76 conditions.

77 **Results**

78 **Correlation between clinical diagnosis and *in vitro* assays**

79 DRESS was the most common presentation of DHR in Southampton tertiary referral
80 centre (53% of diagnosed DHR in 2017-2018) and in our cohort, antibiotics were the
81 dominant causal drugs for this condition (Figure 1a). 5 cases of antibiotic-induced
82 DRESS were selected ('discovery' cohort). Cohort characteristics (median age 49
83 years, IQR: 36-71), are described in Table 1. We confirmed that all identified antibiotic-
84 DRESS cases demonstrated positive *in vitro* responses to stimulation with the culprit
85 antibiotic, whereas no drug-induced responses were detected in tolerant controls (LPA
86 $p = 0.0025$, IFN- γ $p = 0.0025$, Mann-Whitney U test) (Figure 1 b,c).

87 **Antibiotic exposure induces transcriptomic programmes encoding immune** 88 **activation in PBMCs from DRESS patients**

89 To identify transcriptomic biomarkers specific for DRESS induced by antibiotics,
90 discovery cohort PBMCs were co-cultured with culprit drug or control *in vitro* for 24
91 hours before isolation of RNA for transcriptome profiling (Figure 2a). This identified
92 267 drug-specific differentially expressed genes (DEGs) (149 up and 118 down-
93 regulated; EdgeR, FDR $p < 0.05$, $\log_{2}FC \geq |1|$, Figure 2b). Transcript-to-transcript
94 clustering (GraphiaPro, Pearson $r \geq 0.85$, MCL = 1.7) identified 4 main clusters (Figure
95 2c). Clusters 1 and 3, comprising 141 genes in total, were enriched in genes regulating
96 cytokine receptor activity (Cluster 1, FDR $p = 7.67 \times 10^{-7}$) and T cell activation via NFAT
97 (Cluster 3, FDR $p = 1 \times 10^{-3}$, Figure 2d,e). In contrast, genes in clusters 2 and 4 were
98 downregulated, and indicated modulation of innate immune system function (Cluster
99 2, FDR $p = 1.87 \times 10^{-2}$) and reduced integrin interactions (Cluster 4, FDR $p = 1.65 \times 10^{-3}$,
100 Figure 2d,e).

101 **Identification of candidate molecular biomarkers for DRESS**

102 To select a panel of candidate biomarkers, DEGs exceeding $|\logFC| \geq 1.5$ were filtered
103 for the nominal gene expression value (minimum cpm ≥ 4 for all the donors, at least
104 100cpm). The resulting 48 candidate biomarkers were evaluated for predictive value
105 using a random forest algorithm in R (package Ranger, alpha=0.9, trees = 500). The
106 top 10 genes with absolute FC $\geq |2|$ (up and down regulation) and RF importance \geq
107 0.05 (Figure 3a, b) and 12 additional immune-related genes were included in the final
108 candidate biomarker panel (Figure 3a, full list of genes including 2 housekeeping
109 genes in Supplemental Table S1). Unsupervised principal component clustering of the
110 candidate biomarkers confirmed that they efficiently differentiated drug-exposed cells
111 from their media control counterparts (Figure 3c). RNA-seq analysis was validated
112 using RT-qPCR for the top 4 gene transcripts (Supplemental Figure 1) and a
113 customised array card confirming the differential expression profile of all 22 transcripts
114 ($r = 0.9542$ $p = <0.0001$) Figure 3d). The differential expression of the candidate
115 biomarker panel (Figure 3e) highlights that although the signature differentiates drug-
116 exposed cells from the control, a degree of heterogeneity existed in expression of
117 specific genes between different subjects.

118 **DRESS biomarkers are specific to drug hypersensitivity**

119 To determine if the identified biomarker panel was DRESS specific, we undertook a
120 comparative analysis with influenza infection (GSE114588), sepsis (GSE60424),
121 systemic lupus erythematosus (GSE112087) and dermatomyositis (GSE125977).
122 Gene expression in these four conditions differed markedly from DRESS (Figure 4),
123 and showed low correlations between DRESS and influenza (0.351), sepsis (-0.179),

124 systemic lupus erythematosus (0.327), and dermatomyositis (0.321) (Pearson
125 correlation coefficient).

126 **Validation of DRESS gene signature panel**

127 To confirm the candidate molecular biomarker panel, we prospectively identified a
128 ‘validation cohort’ (6 cases of DRESS caused by antibiotics: cefoxitin, vancomycin and
129 teicoplanin) as well as patients tolerant of the same antibiotics (n=7). This group was
130 similar in terms of age, sex, and time to onset (Table 1). Similar to the discovery cohort,
131 positive tests for drug hypersensitivity were demonstrated by T cell functional assays
132 *in vitro* (LPA p = 0.0082, IFN- γ p = 0.0012, Mann-Whitney U test) in all DRESS subjects
133 (Figure 5a, b). To validate the gene signature panel, PBMCs from allergics were
134 challenged with culprit medications, and the 22-candidate biomarker panel analysed.
135 Comparison of culprit drug against media control in DRESS patients (Figure 5c) and
136 between DRESS cohort against tolerant individuals (Figure 5d) showed clearly
137 identifiable differences. In tolerant subjects, the 22 candidate biomarkers tested were
138 only minimally affected following exposure to antibiotics (median change in gene
139 expression relative to *YWHAZ* for each gene $2^{-\Delta\Delta CT} = 1.04$, range: 0.68-1.81),
140 confirming the signature was specific for DRESS. As expected, some heterogeneity in
141 the gene expression patterns between individuals was evident in both tolerant controls
142 and allergic individuals.

143 **An algorithm for analysis of gene expression alterations as a diagnostic** 144 **approach in antibiotic-DRESS**

145 A point attribution system based on observed changes in each of the transcripts from
146 the 22-gene biomarker panel was developed. Scoring 6 DRESS subjects and 7
147 tolerant controls showed statistically significant difference (p = 0.0052, Mann-Whitney
148 U test) when scored against all 22 genes (Figure 5e, full scores listed in Supplemental

149 Table S2). By setting a threshold score of 6, this novel scoring system was able to
150 correctly stratify almost all cases (5 DRESS, 6 controls) with high sensitivity and
151 specificity (83.3% and 85.7% respectively, $p=0.029$, Fisher's exact test).

152 **Machine learning identifies optimal panel of biomarkers differentiating**
153 **antibiotic-DRESS patients from tolerant controls**

154 However, because it was apparent that not all genes contributed equally to the 22-
155 gene scoring matrix that had been developed, we set out to evaluate which gene
156 marker or combination of biomarkers had the highest predictive value for a prospective
157 diagnostic test. Firstly, we took a machine learning approach and trained a random
158 forest algorithm using the validation cohort data (Ranger package, R, $\alpha = 0.9$,
159 $\text{trees}=500$, binary input). The analysis ranked the candidate biomarkers in order of
160 importance for predictive classification (Figure 6a, Supplemental Table S3). For the
161 10 highest ranked markers, receiver operating characteristics (ROC) analysis showed
162 100% sensitivity and 100% specificity (AUC = 1). Secondly, we tested a reduced panel
163 of biomarkers identified by their individually significant differential expression between
164 allergics and tolerants: *STAC*, *GPR183*, *CD40*, *CISH*, *CD4*, and *CCL8* (Figure 6c) in
165 contrast to the other genes in the 22-gene panel (Supplemental Figure 2). By applying
166 our scoring algorithm manually to these 6 genes using a threshold score of 0, we
167 enhanced the diagnostic accuracy as compared to the 22-panel (sensitivity 100%,
168 specificity 85.7%; $p = 0.0047$, Fisher's exact test; Figure 6d; Supplemental Table S4).

169

170 **Discussion**

171 Criteria for diagnosis of DRESS are clear: cutaneous eruption with hematologic
172 abnormalities and systemic involvement, with the addition of HHV-6 reactivation by
173 Japanese criteria (3, 12). However, the optimal diagnostic work-up to identify a causal
174 drug has remained elusive. Key to the management of DRESS is prompt
175 discontinuation of the culprit drug, as the process can be progressive and even result
176 in catastrophic organ failure (4, 13) and latterly autoimmune sequelae. The
177 determination of drug culpability based only on chronological history of drug ingestion
178 is often unreliable because of heterogeneous presentations and sometimes confusing
179 long-latent periods following the introduction of drugs. In addition to this, definitive
180 challenge testing is inadvisable in DRESS, leaving few alternative options for
181 diagnostic assessment. Particularly challenging are patients taking multiple
182 medications simultaneously. Whilst some groups, including ourselves, have utilised *in*
183 *vitro* functional T cell assays in an attempt to elucidate the causal drugs (10, 11, 14),
184 multiple issues restrict the widespread availability of such assays. These include the
185 need for specialist resources and expertise, as well as variation in reported sensitivity
186 of tests suggesting a user-dependent variability (14, 15). There is a clear need for new
187 approaches to this issue.

188 By using a non-hypothesis driven approach to evaluate to identify DRESS activated
189 molecular pathways we sought to maximise the possibility to detect a DRESS-specific
190 signature. Furthermore, such an approach also contributes to better understanding of
191 disease pathogenesis (16, 17). Transcriptomic profiling by RNA sequencing is
192 advantageous as not only does it enable identification of key differentially expressed
193 genes but also has high sensitivity for low abundance transcripts (18, 19). Utilisation

194 of RNAseq in melanoma (20, 21), psoriasis and atopic dermatitis (19) has enabled
195 classification based on phenotype, prognosis, and prediction of intervention outcome.
196 The availability of such technology should therefore be harnessed to further our
197 understanding of cutaneous drug reactions to enable emergent clinical applications.

198 Here, using a multi-method, unbiased analysis approach, we were able to determine
199 22 key genes which were differentially regulated in blood cells from allergic individuals
200 after *in vitro* exposure to the culprit drug. Of the 22 transcripts identified, we used a
201 machine learning approach to select 10 and a more traditional differential expression
202 approach to select 6 with the strongest association with DRESS. *GPR183* (G-protein
203 coupled receptor 183; syn. Epstein-Barr virus (EBV)-induced gene 2, *EBI2*) is
204 expressed in lymphocytes where, by binding oxysterols, it creates a chemotactic
205 gradient to direct movement of B-cells, T-cells, dendritic cells and
206 monocytes/macrophages (22, 23). Down-regulation of GPR183 as induced by
207 exposure to the culprit drug in allergics in this study, has been shown to enhance
208 production of type 1 IFNs and inflammatory cytokines by blood dendritic cells (24).
209 Therefore, this may reflect an important pathway for enhanced drug-antigen
210 presentation to CD8+ T cells in DRESS, which may contribute to the organ damage
211 seen in this condition (25). CD4 down-regulation is well established as a consequence
212 of Th2 activation. The down-regulation of CD4 expression in allergics following drug
213 exposure as seen here is interesting because evidence of drug-specific HLA-
214 restriction in DRESS has so far only identified MHC Class I alleles (26). These results
215 therefore support the possibility that drug-specific CD4+ T cells may play an important
216 role in DRESS. Further evidence of the role of CD4 activation is suggested by the
217 enhanced CCL8 expression in allergics. CCL8 has been shown to be central to
218 recruiting IL-5 producing Th2 cells (27), which in turn regulate eosinophilia, thus linking

219 these transcript changes to the hallmarks of DRESS. In addition, *CISH* (cytokine
220 inducible SH2 containing protein), was found to be upregulated by culprit drug
221 exposure in allergics and has been shown to be a marker of allergen-specific Th2 cells
222 (28). Taken together, these data suggest an important role for drug-specific Th2 cells
223 in DRESS and raise the possibility of therapeutic targeting of the Th2 pathway in acute
224 disease. Recent drugs are already licensed for such purposes to treat other Th2
225 diseases including those targeting IL-4Ra, and anti-IL5. *STAC* (SH3 and cysteine-rich
226 containing protein), a mediator of calcium-dependent inactivation, was also up-
227 regulated in DRESS and whilst it is likely to be important in regulating inflammation
228 (29), the precise role of *STAC1* (as here), remains to be established.

229 However, for diagnostic approaches, the sensitivity and specificity of the identified
230 signature is key. Using a machine learning approach, we were able to select 10 genes
231 which were demonstrated a sensitivity and specificity of 100%. However, to
232 demonstrate conservative assessment of the utility of these biomarkers in DRESS, we
233 showed that a combined panel of six genes, identified by differential gene expression
234 statistics within the validation cohort allowed robust identification of the causative
235 antibiotic in DRESS with greater accuracy than that of the initial 22 gene algorithm
236 (sensitivity 100%, specificity 85.7%). Furthermore, we showed that these gene
237 expression profiles were not evident in healthy volunteers who tolerated the drugs in
238 question, and also that they were not induced in other inflammatory conditions, which
239 can mimic or precede onset of DRESS. Accordingly, the systems biology approach
240 confirmed that the proposed diagnostic panel is a distinct gene expression signature
241 for DRESS.

242

243 Kim et al. recently applied single-cell RNA sequencing (scRNA-seq) to a single case
244 of DRESS, and identified transcriptomal alterations in associated with proliferation,
245 migration, activation and signalling pathways, which then informed therapeutic options
246 (30). Whilst such an approach may be ideal, scRNA-seq applicability to clinical
247 practice is limited by high cost and need for expertise. For diagnostic purposes, we
248 validated that the transcriptomic signature identified here could be reliably interrogated
249 by TaqMan array cards, which would be amenable to utilisation in non-specialist
250 routine pathology laboratories. However, this approach would also be suited to a hub
251 and spoke model for diagnostic testing because the good stability of frozen lysate prior
252 to RNA extraction would enable batched transport and processing if necessary. Whilst
253 downstream processing does require a degree of expertise, centralisation of this would
254 reduce technical variability. It also remains possible that by subjecting greater
255 numbers of cases to molecular profiling, patterns in the gene signature signal could
256 identify hereto-unrecognised DRESS endotypes characterised by a correlation
257 between clinical features and molecular signature (5, 6, 8, 31-34). A wholly *ex vivo*
258 diagnostic test is safe and requires only a minimal amount of blood sampling from
259 patients. Moreover, as the incidence of DRESS is relatively low, between 1:1000 to
260 1:10,000 drug exposures (35), our preferred approach is to utilise a paired analysis
261 (control vs drug) in diagnostic samples, which mitigates the need for validation of
262 normal ranges for population-wide background correction.

263 The limitations of this work include the sample size, and the restriction of the allergic
264 cohorts tested to antibiotic induced DRESS. Whilst it remains uncertain whether this
265 transcriptomic signature can be applied to other phenotypes e.g. Stevens-Johnson
266 syndrome, we accepted a high stringency in the clinical phenotype inclusion criteria
267 here because it would minimise sampling error and reduce the size of the cohort

268 required to identify a valid test. Additionally, our tested patients with DRESS were
269 otherwise well at the time of sampling, and therefore, we have no data on the utility of
270 this test in acutely ill patients. However, we did show that the diagnostic panel is not
271 identified in cohorts with other severe infections or other inflammatory skin rashes,
272 suggesting that the gene set measured here is specific to DRESS.

273 In summary, we show that a carefully selected panel of gene transcripts, which can be
274 measured on a pre-printed array card, offers a useful diagnostic test in antibiotic-
275 associated DRESS with a conservative assessment of 85.7% prediction rate (0.48-
276 0.99 95% CI), and sensitivity of 100% and specificity of 85.7%, but that this could be
277 higher with further refinement and validation. The advantage of this approach is that
278 such gene card testing is familiar to hospital laboratories and therefore this technology
279 is scalable for routine use. Further work is required to determine whether the same
280 panel can be used for other drug hypersensitivity reactions, but the results here
281 demonstrate a proof of concept for the development of gene signature panels for
282 diagnosis of T cell mediated disease.

283

284 **Methods**

285 **Patients and controls**

286 Patients diagnosed with delayed hypersensitivity reaction (DHR) on clinical grounds
287 by consultant dermatologists experienced in the recognition of these reactions were
288 recruited to the study through the Department of Dermatology, University Hospital
289 Southampton NHS Foundation Trust. Eleven DRESS patients with symptoms
290 corresponding to diagnostic criteria for DRESS were identified as confirmed by
291 RegiSCAR score ≥ 3 (4). Only subjects with no active infections or malignancies and
292 without history of immunosuppression, including due to medications, were included. 7
293 comparative tolerant controls (treated with a relevant antibiotic, but without DHR
294 symptoms) were also tested. Patients were divided into a 'discovery' cohort (5 patients
295 with DRESS caused by antibiotics: cefoxitin, dapsone, teicoplanin, or vancomycin) and
296 a 'validation' cohort (6 patients with DRESS) (Table 1). All testing was undertaken on
297 fresh (not frozen) samples isolated from anticoagulated peripheral blood. The tests
298 were undertaken on average (mean) 370.7 days from rash onset (median: 124 days,
299 IQR 71-347).

300 **Lymphocyte Proliferation and ELISpot test**

301 Lymphocyte proliferation test and IFN- γ enzyme-linked immunosorbent spot assay
302 (ELISpot) are routinely performed in our laboratory as we previously described (10,
303 11). Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in the
304 presence of the relevant drug at four concentrations overnight at 37°C, 5% CO₂ on
305 pre-coated ELISpot plates (Millipore, UK; Mabtech, Sweden) and for 5 days
306 (lymphocyte proliferation assay, LPA) respectively, in triplicate. Internal validation of
307 the assays was achieved with negative (medium) and positive (phytohemagglutinin,

308 PHA) controls. For ELISpot testing, after overnight culture, plates were washed and
309 developed as per manufacturer's instructions. Spot-forming units per million cells
310 were enumerated using an automated ELISpot reader (Autoimmun Diagnostika
311 GmbH, Strassberg, Germany). Positive responses were recorded as those responses
312 greater than the mean of all the background samples plus 2x the standard deviation
313 (SD) of the background. For LPA testing, on day 5, 1 μ Ci/ml of 3H-thymidine
314 (Amersham, UK) was added, and the cells harvested 6 hours later for scintillation
315 counting. The stimulation index (SI) was calculated as the fold difference between
316 counts per minute recorded in wells stimulated by drug over the negative control. SI
317 greater than 2 was considered a positive result (Table 1).

318 **RNA isolation and purification**

319 PBMCs (7.5×10^5 cells per well, in duplicates) were incubated for 24 hours with medium
320 (control) or culprit drug before RNA harvesting for transcriptomic analysis. Following
321 24-hour stimulation with drug or control medium, PBMCs were harvested, washed,
322 and suspended in RLT lysing buffer (Qiagen, UK) before storage at -20°C . Each
323 sample was thawed immediately before RNA isolation and whole transcriptome RNA-
324 sequencing. RNA extraction and purification were performed according to
325 manufacturer's protocol (RNeasy Plus Mini Kit, Qiagen, UK). DNA contamination in
326 the collected RNA was eliminated by use of gDNA Eliminator spin column. RNA
327 quantity and quality checking were performed using the NanoDrop™ 1000
328 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100
329 Bioanalyzer using an RNA 6000 Nano LabChip kit (Agilent Technologies, Cork,
330 Ireland). All samples displayed a 260/280 ratio >1.8 and RNA integrity numbers (RIN)
331 > 7.7 . Purified RNA samples were stored at -80°C until use.

332 **mRNA-Seq library construction and sequencing**

333 Total RNA samples were subjected to indexed cDNA library construction, using the
334 Illumina TruSeq poly(A) + RNA-Seq library construction, according to the
335 manufacturer's instructions. For sequencing, all samples were pooled in a single pool
336 and sequenced on 3 lanes, yielding 75-bp paired-end reads, using an Illumina HiSeq
337 4000 platform (an outsourced service at the Oxford Genomics Centre).

338 **Bioinformatics analysis**

339 Quality-controlled reads were aligned to the reference genome GRCh37.EBVB95-
340 8wt.ERCC using the HISAT aligner. Alignments were counted for each gene using the
341 featureCounts package (36). Aligned reads were further analysed in R using the
342 Bioconductor suite of packages. Filtered trimmed mean of M values (TMM) normalised
343 counts per million (cpm) (EdgeR, filtering out genes less than two gene counts in at
344 least half of the samples) were used for downstream analyses (37). Determination of
345 differentially expressed genes (DEG) was performed using EdgeR with a nested
346 paired design (37). The expected false discovery rate (FDR) was estimated using the
347 Benjamini-and-Hochberg method. An FDR adjusted $p \leq 0.05$ was considered
348 significant.

349 RNA-seq data were deposited in accordance with MIAME guidelines, in Gene
350 Expression Omnibus (GEO) under accession number GSE160369.

351 **Quantitative Reverse Transcription-PCR (qRT-PCR)**

352 The expression of chosen genes was validated with quantitative PCR using the
353 TaqMan gene expression assays for target genes: *YWHAZ* (Hs01122445_g1), *STAC*
354 (Hs00182385_m1), *CISH* (Hs00367082_g1), *FN1* (Hs01549976_m1) and *CD4*
355 (Hs01058407_m1) (Applied Biosystems, Life Technologies, UK) in PBMCs isolated

356 from whole blood. RNA extraction (RNeasy Plus Mini Kit, Qiagen) and cDNA reverse
357 transcription, including RT-negative control, (High-Capacity cDNA Reverse
358 Transcription Kit, Applied Biosystems; ThermoFisher Scientific UK) were carried out
359 according to the manufacturer's protocol. qPCR was performed in 384-well plate
360 assay, using Applied Biosystems 7900HT Fast Real-Time PCR System. Gene
361 expression levels were normalised to housekeeping gene expression (*YWHAZ*).

362 **TaqMan array card**

363 Customised RT-PCR cards from Applied Biosystems
364 (<http://www.appliedbiosystems.com>) were used in the quantitative analysis of the 22
365 selected candidate genes. Eight samples with two technical duplicates were tested
366 per card. The 384-well microfluidic card was preloaded with our chosen genes. Each
367 cDNA sample was added to an equal volume of mastermix (TaqMan, Applied
368 Biosystems) and then loaded onto the array card. PCR amplification was performed
369 using a 7900HT Fast Real-time PCR System (Applied Biosystems) following the
370 protocol described by the manufacturer. The threshold cycle (CT) was automatically
371 given by the SDS2.2® software package (Applied Biosystems). Relative expression
372 of each gene was normalized to *YWHAZ* as the sole housekeeping gene, and log₂-
373 transformed for analysis ($RQ=2^{-\Delta\Delta Ct}$). All data were generated in duplicate for each
374 gene expression per sample.

375 **Evaluation of diagnostic performances**

376 Ranking of detected genes for selection of candidate biomarker genes was done using
377 absolute log fold change (FC) cut off ($\log FC \geq |1.5|$) calculated using generalised linear
378 model in EdgeR, combined with minimum expression levels for all donors (minimum
379 $cpm \geq 4$, maximum $cpm \geq 100$). Random forest analysis was performed using package

380 Ranger in R (importance measure = impurity, number of trees = 500, alpha = 0.9).
381 Combinatorial panel analysis with top 10 candidate genes identified on random forest
382 algorithm were performed using CombiRoc webtool (38). Receiver-operating
383 characteristic (ROC) curves were calculated in order to assess the diagnostic power
384 of the gene combination by the area under the curve (AUC) of the ROC curve.
385 Potential biomarkers were considered valuable if sensitivity and specificity were >85%,
386 as well as AUC \geq 0.8.

387 **Comparison with systemic inflammatory conditions**

388 Datasets for 4 systemic conditions: influenza, sepsis, systemic lupus erythematosus
389 and dermatomyositis were downloaded from publically available genomic data
390 repositories (GSE114588, GSE60424, GSE112087, GSE125977). FASTQ files for
391 GSE114588 and GSE60424 were aligned using Kallisto (39) against the GRCh38
392 human reference genome followed by differential analysis using Sleuth (40). Disease
393 describing gene expression signatures were generated by comparing TMM
394 normalised gene expression levels between experimental and control group using
395 EdgeR package (37) (FC \geq log2 and adjusted p value <0.05). Raw RNA-seq data for
396 GSE112087 was quantified to gene-level counts using the ARCHS4 pipeline (41) with
397 similar thresholds as the other datasets. Published values (FC \geq log2) relating to
398 dermatomyositis subjects from GSE125977 were extracted for comparative analysis.
399 Enrichment analyses performed to published gene sets associated with these four
400 inflammatory conditions (influenza 2, sepsis 5, systemic lupus erythematosus 5,
401 dermatomyositis 1) did not show significant overlap (enrichment scores: 0.27-0.55,
402 FDR<0.05).

403 **Functional enrichment analysis**

404 Gene set enrichment analysis (GSEA) (42, 43) was performed for complete DRESS
405 dataset (11747 transcripts, average were calculated for transcripts associated with the
406 same genes (3 genes)) using curated gene signatures of 4 inflammatory diseases
407 above downloaded from MSigDB (Molecular Signatures Database v7.1)
408 (**Supplemental Table S5**). Largest collections relating to dermatomyositis from
409 DisGeNET platform (v7.0) (44, 45) were used in view of no available curated gene
410 sets for this disease on other MSigDB platform (42, 46). Similarities were examined at
411 cut-off of FDR-adjusted p-value <0.05 and Enrichment Scores.

412 **Scoring classification**

413 Mean values for each biomarker gene was calculated from RT-qPCR data from 6
414 DRESS subjects tested using the array card and compared against logFC RNAseq
415 data to determine up- and down-regulated genes in the signature panel. For every
416 transcript expression which matched this expected change, 1 point was added whilst
417 1 point was subtracted if direction of change was opposite to that of the identified
418 signature. Log₂ 2^{-ΔΔCt} values for each subject (6 DRESS, 7 tolerant controls) were
419 used in this scoring. No points were added or subtracted if values fell between -0.25
420 and 0.25.

421 **Statistics**

422 Statistical analyses were performed using Prism 8.1 (GraphPad Software) and
423 methods embedded in bioinformatics pipelines (Generalised Linear Model, EdgeR,
424 Benjamini-and-Hochberg FDR-corrected p-value test). Mann-Whitney U test was used
425 for comparison between non-matched non-parametric samples and Fisher's exact test
426 for contingency table analysis. Correlations between RNA-seq and qPCR results were

427 performed using Pearson test and linear regression analysis. Data were considered
428 significant at $p < 0.05$.

429 **Study approval:** Ethical approval for this project was obtained from the UK Research
430 Ethics Service (RES) of the national Health Research Authority (17/NE/0346) for
431 subject recruitment at University Hospital Southampton NHS Trust. Written informed
432 consent from all participants was obtained prior to inclusion in the study.


433 **Author contributions:** YXT and WYH performed experiments, analysed data and
434 drafted the manuscript. AFV analysed data and provided technical support. CG
435 performed experiments. JW analysed data. PSF contributed to study design and
436 oversaw writing of the manuscript. MEP and MAJ designed the research study,
437 analysed data and oversaw writing of the manuscript.

438 **Acknowledgements:** This work was supported by the British Skin Foundation [grant
439 number BSF8021]. MEP is funded by the Wellcome Trust [grant number
440 109377/Z/15/Z]. The authors acknowledge the use of the IRIDIS High Performance
441 Computing Facility, and associated support services at the University of
442 Southampton, in the completion of this work as well as assistance from Christopher
443 Woelk PhD, and Tilman Sanchez-Elsner PhD. We thank the Oxford Genomics
444 Centre at the Wellcome Centre for Human Genetics (funded by Wellcome Trust
445 grant reference 203141/Z/16/Z) for the generation and initial processing of the
446 sequencing data.

447

448 **Figures**

449 **Figure 1**




450

451 **Figure 1:** Causative drugs in referred DRESS cases and confirmation of clinically suspected antibiotic
452 by positive T cell assay in DRESS 'discovery' cohort. a) Prevalence of causative drug groups in
453 DRESS cases referred to Southampton NHS Foundation Trust between 2017-2018. b) Lymphocyte
454 Proliferation Test (LPA) measured as stimulation index (SI) of proliferation induced by drug versus
455 media control and c) IFN- γ release in drug-induced responses measured by ELISpot in 'discovery'
456 cohort subjects (n=5), and control patients tolerant of similar antibiotics (n=7). Each data point
457 represents maximum measured response to tested drug. Horizontal solid lines indicate group median.
458 Horizontal dotted line shows positive result threshold. Mann-Whitney U test used for assessing
459 statistical significance, * = p-value < 0.05. DRESS = drug reaction with eosinophilia and systemic
460 symptoms, IFN- γ ELISpot = interferon-gamma enzyme-linked immunosorbent spot, LPA = lymphocyte
461 proliferation assay, NSAID = non-steroidal anti-inflammatory, PPI = protein pump inhibitor, SFU = spot
462 forming unit

463

464 **Figure 2**




465

466 **Figure 2:** Testing protocol and identification of Differentially Expressed Genes. a) PBMCs were cultured
 467 in culture media supplemented or not with culprit drug at the optimised concentration for 24 hours before
 468 RNA extraction. b) MA plot representation of 267 drug-specific DEGs (149 up-regulated, red; 118 down-
 469 regulated, blue; FDR $p < 0.05$, blue line depicts a threshold of $\log FC \geq |1|$). c-e) Transcript-to-transcript
 470 correlation network analysis of gene expression changes induced by culprit drug in DRESS patients
 471 (discovery cohort, $n=5$). 4 major clusters shown, cluster 1 (green, $n=103$ genes), cluster 2 (purple, $n=$
 472 76 genes), cluster 3 (brown, $n=39$ genes), cluster 4 (grey, $n=32$ genes). Each node (dot) indicates a
 473 transcript, each line defines the Pearson correlation coefficient between a pair of nodes (GraphiaPro,
 474 Pearson $r \geq 0.85$, MCL = 1.7). d) Median gene expression profiles in clusters 1-4 in control (grey) and
 475 drug exposed cells (white). Box and whiskers indicate median \pm range. e) Key processes identified
 476 by gene ontology analysis specific to each cluster (ToppGene, FDR cut-off 0.05, cluster 1: FDR $p =$
 477 7.67×10^{-7} , cluster 2: FDR $p = 1.87 \times 10^{-2}$; cluster 3: FDR $p = 1 \times 10^{-3}$; cluster 4: FDR $p = 1.65 \times 10^{-3}$).
 478 DEG=differentially expressed gene, FC=fold change, FDR=false discovery rate

479

480 **Figure 3**




481

482

483 **Figure 3:** Identification of candidate biomarker genes. a) Selection of candidate biomarkers. Following
 484 identification of 524 DEGs by comparison of drug-stimulated and media (unstimulated) in the discovery
 485 cohort (EdgeR package, FDR<0.05), genes with $|\log_2FC| \geq 1.5$ and $cpm > 100$ were selected. 10 genes
 486 with absolute FC ≥ 2 and random forest (RF) importance ≥ 0.05 were selected from the filtered genes
 487 and combined with 12 immune-related genes to form the gene panel. b) Volcano plot of genes
 488 measured in DRESS discovery cohort, differentiating responses to culprit drug versus media control.
 489 Differentially expressed genes (FDR<0.05) shown in blue (up-regulated genes on right, down-regulated
 490 on left), genes selected indicated in red. c) PCA clustering (first two components) comparing signature
 491 panel gene expression induced by culprit drug (red) and media (blue) after 24-hour culture. d)
 492 Comparison of gene changes detected in panel genes using RNAseq and PCR with customised
 493 microfluidic array card in a single subject, normalised to YWHAZ gene expression. e) Heatmap
 494 depicting changes in expression of selected 22 candidate biomarkers in 5 antibiotic-DRESS patients
 495 exposed to culprit drug versus media control. Colour indicates the expression change in logFC. Red:
 496 upregulated genes; blue: downregulated genes. DEG=differentially expressed gene, FC=fold change,
 497 PC = principal component, PCA = principal component analysis, RF = random forest

498

499 **Figure 4**




500

501 **Figure 4.** DRESS biomarkers are specific to drug hypersensitivity. Heatmap depicting expression of
502 biomarker gene panel in samples sourced from public data repositories including influenza infection
503 (GSE114588), sepsis (GSE60424), systemic lupus erythematosus (GSE112087) and dermatomyositis
504 (GSE125977). Colour indicates the expression change compared to DRESS allergics. Red:
505 upregulated genes, Blue: downregulated genes.

506

507 **Figure 5**




508

Figure 5. DRESS validation cohort confirms specificity of biomarker panel. a-b) Characteristics of *in vitro* responses to culprit drug in antibiotic-DRESS validation cohort (n=6) and control patients tolerant of similar antibiotics (n=7). a) Lymphocyte Proliferation Test (LPA) measured as stimulation index (SI) of proliferation induced by drug versus media control and b) IFN- γ release in drug-induced responses measured by ELISpot. Each data point represents maximum measured response to tested drug. Horizontal solid lines indicate group median. Horizontal dotted line shows positive result threshold. Mann-Whitney U test used for statistical significance (** = $p < 0.01$). c) Heatmap depicting changes in expression of selected 22 candidate biomarkers in validation DRESS cohort exposed to culprit drug versus media control. Colour indicates the expression change in logFC. Red: upregulated genes; blue: downregulated genes. d) Heatmap depicting changes in expression of selected 22 candidate biomarkers in validation DRESS cohort versus tolerant patients. Colour indicates the expression change in logFC. Red: upregulated genes, Blue: downregulated genes. e) Box and whisker plot showing cumulative scoring using 22 biomarker genes compared to expected expression alterations based on signature panel. Error bars indicate data range. Horizontal red line indicates threshold score considered positive. (** = $p < 0.01$, Fisher's exact test). IFN- γ ELISpot = interferon-gamma enzyme-linked immunosorbent spot, SFU = spot forming unit

526

527 **Figure 6**



528

529 **Figure 6.** Optimisation of biomarker panel to differentiate DRESS due to antibiotics from tolerant
530 controls. a) Gene importance for the biomarker panel measured by random forest, 10 genes with the
531 highest importance shown (Ranger package, R, alpha = 0.9, trees=500, binary input).b) CombiROC
532 analysis of 10 genes with highest importance (AUC = 1, sensitivity = 100%, specificity = 100%). c)
533 Expression of genes in biomarker panel measured by qPCR in drug allergic patients (grey) and controls
534 tolerant to specified antibiotics (white). Change induced in expression shown for 6 genes reaching
535 statistical difference (* = $p < 0.05$, ** = $p < 0.01$) in expression change between patient cohorts ($2^{-\Delta\Delta CT}$
536 versus *YWHAZ* housekeeping gene). Box and whiskers indicate median and data range d) Box and
537 whisker plot of novel scoring system using 6 select biomarker genes to stratify DRESS and control
538 subjects. Error bars indicate data range. Horizontal red line indicates threshold score considered
539 positive. (** = $p < 0.01$, Fisher's exact test) ROC = receiver operator characteristic, AUC = area under
540 curve, CI = confidence interval.

541 **Tables**

542 **Table 1:** Demographics of tested subjects and comparative T-cell assay results

Cohort	Sex	Age range (years)	Phenotype	Drug	RegiSCAR score	LPA (Cmax SI)	IFN- γ [Cmax – (background + 2x SD)]
Discovery n=5	M	35-40	DRESS	Cefoxitin	3	69.9*	254
	M	25-30	DRESS	Cefoxitin	5	63.4*	74
	F	75-80	DRESS	Vancomycin	3	7.67*	10
	M	45-50	DRESS	Teicoplanin	6	50.4*	175
	F	70-75	DRESS	Dapsone	5	18.5*	111
Validation n=6	M	20-25	DRESS	Cefoxitin	3	13.7*	20
	F	15-20	DRESS	Cefoxitin	3	3.6*	21
	M	35-40	DRESS	Cefoxitin	3	2.3*	39
	M	70-75	DRESS	Vancomycin	5	2.5*	554
	F	40-45	DRESS	Vancomycin	4	18.4*	113
	F	80-85	DRESS	Teicoplanin	3	1.3	605
Tolerant controls n=7	F	25-30	Tolerant	Cefoxitin	NA	1.7	Neg
	M	20-25	Tolerant	Cefoxitin	NA	0.7	Neg
	F	80-85	Tolerant	Vancomycin	NA	2.1	Neg
	F	80-85	Tolerant	Vancomycin	NA	0.6	Neg
	M	55-60	Tolerant	Vancomycin	NA	1.4	Neg
	F	65-70	Tolerant	Vancomycin	NA	1.2	Neg
	M	60-65	Tolerant	Teicoplanin	NA	0.8	Neg

543 Cmax = maximal concentration, IFN = interferon, LPA = lymphocyte proliferation assay, NA = not
 544 applicable; Neg = negative, RegiSCAR = registry of Severe Cutaneous Adverse Reaction (RegiSCAR
 545 score: 2-3 possible case, 4-5 probable case, >5 definite case), SD = standard deviation, * = positive
 546 result (SI >2)

547 **References:**

- 548 1. Brockow K, Ardern-Jones MR, Mockenhaupt M, Aberer W, Barbaud A, Caubet JC, et al. EAACI
549 position paper on how to classify cutaneous manifestations of drug hypersensitivity. *Allergy*.
550 2019;74(1):14-27.
- 551 2. Ardern-Jones MR, Mockenhaupt M. Making a diagnosis in severe cutaneous drug
552 hypersensitivity reactions. *Curr Opin Allergy Clin Immunol*. 2019;19(4):283-93.
- 553 3. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been
554 sufficiently established on the basis of typical clinical features and viral reactivations. *Br J Dermatol*.
555 2007;156(5):1083-4.
- 556 4. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction
557 with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction.
558 Results from the prospective RegiSCAR study. *Br J Dermatol*. 2013;169(5):1071-80.
- 559 5. Chen Y-C, Chiu H-C, Chu C-Y. Drug Reaction With Eosinophilia and Systemic Symptoms: A
560 Retrospective Study of 60 Cases. *Arch Dermatol*. 2010;146(12):1373-9.
- 561 6. Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M,
562 Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and
563 systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. *Allergology international*
564 : official journal of the Japanese Society of Allergology. 2016;65(4):432-8.
- 565 7. Martínez-Cabriales SA, Rodríguez-Bolaños F, Shear NH. Drug Reaction with Eosinophilia and
566 Systemic Symptoms (DRESS): How Far Have We Come? *Am J Clin Dermatol*. 2019;20(2):217-36.
- 567 8. Wu X, Yang F, Chen S, Xiong H, Zhu Q, Gao X, et al. Clinical, Viral and Genetic Characteristics
568 of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in Shanghai, China. *Acta Derm*
569 *Venereol*. 2018;98(4):401-5.
- 570 9. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, et al. ALDEN, an algorithm
571 for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis:
572 comparison with case-control analysis. *Clin Pharmacol Ther*. 2010;88(1):60-8.
- 573 10. Haw WY, Polak ME, McGuire C, Erlewyn-Lajeunesse M, Ardern-Jones MR. In vitro rapid
574 diagnostic tests for severe drug hypersensitivity reactions in children. *Ann Allergy Asthma Immunol*.
575 2016;117(1):61-6.
- 576 11. Polak ME, Belgi G, McGuire C, Pickard C, Healy E, Friedmann PS, et al. In vitro diagnostic
577 assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. *Br J*
578 *Dermatol*. 2013;168(3):539-49.
- 579 12. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DIHS)/drug reaction with
580 eosinophilia and systemic symptoms (DRESS): An update in 2019. *Allergology international* : official
581 journal of the Japanese Society of Allergology. 2019;68(3):301-8.
- 582 13. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity
583 syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). *Semin Cutan Med Surg*.
584 1996;15(4):250-7.
- 585 14. Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In
586 vitro tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position
587 paper. *Allergy*. 2016;71(8):1103-34.
- 588 15. Mayorga C, Ebo DG, Lang DM, Pichler WJ, Sabato V, Park MA, et al. Controversies in drug
589 allergy: In vitro testing. *J Allergy Clin Immunol*. 2019;143(1):56-65.
- 590 16. Reuter Jason A, Spacek DV, Snyder Michael P. High-Throughput Sequencing Technologies.
591 *Molecular Cell*. 2015;58(4):586-97.
- 592 17. Finotello F, Rieder D, Hackl H, Trajanoski Z. Next-generation computational tools for
593 interrogating cancer immunity. *Nature reviews Genetics*. 2019;20(12):724-46.
- 594 18. Jabbari A, Suárez-Fariñas M, Dewell S, Krueger JG. Transcriptional profiling of psoriasis using
595 RNA-seq reveals previously unidentified differentially expressed genes. *J Invest Dermatol*.
596 2012;132(1):246-9.

- 597 19. Schwingen J, Kaplan M, Kurschus FC. Review-Current Concepts in Inflammatory Skin Diseases
598 Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis. *Int J Mol*
599 *Sci.* 2020;21(3).
- 600 20. Berger MF, Levin JZ, Vijayendran K, Sivachenko A, Adiconis X, Maguire J, et al. Integrative
601 analysis of the melanoma transcriptome. *Genome research.* 2010;20(4):413-27.
- 602 21. Valsesia A, Rimoldi D, Martinet D, Ibberson M, Benaglio P, Quadroni M, et al. Network-
603 guided analysis of genes with altered somatic copy number and gene expression reveals pathways
604 commonly perturbed in metastatic melanoma. *PLoS ONE.* 2011;6(4):e18369.
- 605 22. Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols direct immune
606 cell migration via EBI2. *Nature.* 2011;475(7357):524-7.
- 607 23. Benned-Jensen T, Norn C, Laurent S, Madsen CM, Larsen HM, Arfelt KN, et al. Molecular
608 characterization of oxysterol binding to the Epstein-Barr virus-induced gene 2 (GPR183). *The Journal*
609 *of biological chemistry.* 2012;287(42):35470-83.
- 610 24. Chiang EY, Johnston RJ, Grogan JL. EBI2 is a negative regulator of type I interferons in
611 plasmacytoid and myeloid dendritic cells. *PLoS ONE.* 2013;8(12):e83457.
- 612 25. Picard D, Janela B, Descamps V, D'Incan M, Courville P, Jacquot S, et al. Drug reaction with
613 eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. *Sci Transl Med.*
614 2010;2(46):46ra62.
- 615 26. Mullan KA, Anderson A, Illing PT, Kwan P, Purcell AW, Mifsud NA. HLA-associated
616 antiepileptic drug-induced cutaneous adverse reactions. *Hla.* 2019;93(6):417-35.
- 617 27. Islam SA, Chang DS, Colvin RA, Byrne MH, McCully ML, Moser B, et al. Mouse CCL8, a CCR8
618 agonist, promotes atopic dermatitis by recruiting IL-5+ T(H)2 cells. *Nature immunology.*
619 2011;12(2):167-77.
- 620 28. Nakajima Y, Tsuge I, Kondo Y, Komatsubara R, Hirata N, Kakami M, et al. Up-regulated
621 cytokine-inducible SH2-containing protein expression in allergen-stimulated T cells from hen's egg-
622 allergic patients. *Clin Exp Allergy.* 2008;38(9):1499-506.
- 623 29. Flucher BE, Campiglio M. STAC proteins: The missing link in skeletal muscle EC coupling and
624 new regulators of calcium channel function. *Biochimica et biophysica acta Molecular cell research.*
625 2019;1866(7):1101-10.
- 626 30. Kim D, Kobayashi T, Voisin B, Jo JH, Sakamoto K, Jin SP, et al. Targeted therapy guided by
627 single-cell transcriptomic analysis in drug-induced hypersensitivity syndrome: a case report. *Nature*
628 *medicine.* 2020;26(2):236-43.
- 629 31. Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, et al. Sequelae in 145
630 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic
631 symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse
632 Reactions (ASCAR). *J Dermatol.* 2015;42(3):276-82.
- 633 32. Wang L, Mei X-L. Drug Reaction with Eosinophilia and Systemic Symptoms: Retrospective
634 Analysis of 104 Cases over One Decade. *Chin Med J.* 2017;130(8):943-9.
- 635 33. Eshki M, Allanore L, Musette P, Milpied B, Grange A, Guillaume JC, et al. Twelve-year analysis
636 of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable
637 multiorgan failure. *Arch Dermatol.* 2009;145(1):67-72.
- 638 34. Agier MS, Boivin N, Maruani A, Giraudeau B, Gouraud A, Haramburu F, et al. Risk assessment
639 of drug-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a
640 disproportionality analysis using the French Pharmacovigilance Database. *Br J Dermatol.*
641 2016;175(5):1067-9.
- 642 35. Fiszenson-Albala F, Auzevie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-
643 month prospective survey of cutaneous drug reactions in a hospital setting. *Br J Dermatol.*
644 2003;149(5):1018-22.
- 645 36. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning
646 sequence reads to genomic features. *Bioinformatics.* 2014;30(7):923-30.

- 647 37. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential
648 expression analysis of digital gene expression data. *Bioinformatics*. 2010;26(1):139-40.
- 649 38. Mazzara S, Rossi RL, Grifantini R, Donizetti S, Abrignani S, Bombaci M. CombiROC: an
650 interactive web tool for selecting accurate marker combinations of omics data. *Sci Rep*.
651 2017;7:45477.
- 652 39. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq
653 quantification. *Nature biotechnology*. 2016;34(5):525-7.
- 654 40. Pimentel H, Bray NL, Puente S, Melsted P, Pachter L. Differential analysis of RNA-seq
655 incorporating quantification uncertainty. *Nat Methods*. 2017;14(7):687-90.
- 656 41. Lachmann A, Torre D, Keenan AB, Jagodnik KM, Lee HJ, Wang L, et al. Massive mining of
657 publicly available RNA-seq data from human and mouse. *Nature communications*. 2018;9(1):1366.
- 658 42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set
659 enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
660 *Proceedings of the National Academy of Sciences of the United States of America*.
661 2005;102(43):15545-50.
- 662 43. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-
663 responsive genes involved in oxidative phosphorylation are coordinately downregulated in human
664 diabetes. *Nature genetics*. 2003;34(3):267-73.
- 665 44. Piñero J, Queralt-Rosinach N, Bravo À, Deu-Pons J, Bauer-Mehren A, Baron M, et al.
666 DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes.
667 *Database : the journal of biological databases and curation*. 2015;2015:bav028.
- 668 45. Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The
669 DisGeNET knowledge platform for disease genomics: 2019 update. *Nucleic acids research*.
670 2020;48(D1):D845-d55.
- 671 46. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular
672 Signatures Database (MSigDB) hallmark gene set collection. *Cell systems*. 2015;1(6):417-25.